Image Analysis Group (IAG), known for its expertise in clinical trial imaging and AI-driven biomarkers, is furthering its footprint in the United States with a new office in Cambridge, Massachusetts. This strategic move places IAG’s operational and business development teams in the heart of the Boston area, a hub for biotechnology and pharmaceutical companies. The new location is set to enhance the company’s ability to forge stronger partnerships and offer local support for clinical trials within the region.
The Cambridge office will play a pivotal role in IAG’s ongoing efforts across various therapeutic sectors, such as oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. By situating itself closer to sponsors and contract research organizations, IAG aims to improve collaboration on Phase I–III clinical trials and imaging-intensive development programs. The expansion is also expected to generate local job opportunities, with anticipated hires in clinical imaging operations, data science, regulatory support, and business development over the next year to two years.
IAG’s new office will bolster its comprehensive imaging services which include consulting on clinical trial design, optimizing imaging protocols, conducting centralized image analysis, and delivering data in a regulatory-compliant manner. Being part of the vibrant Boston life-sciences ecosystem will enable the company to work more effectively with biotechnology firms, pharmaceutical companies, academic institutions, and clinical research centers.
Globally, IAG supports clinical trials across North America, Europe, and the Asia-Pacific region. It collaborates with pharmaceutical, biotechnology, and medical technology companies, as well as contract research organizations, on multi-center studies. IAG’s global operations focus on providing standardized imaging protocols, centralized data harmonization, and consistent imaging analysis for international trials.
Founded in 2007 and headquartered in London, IAG operates as an imaging Clinical Research Organization (iCRO). The company assists pharmaceutical, biotechnology, and medical technology firms with imaging-based clinical trial endpoints. Operating across various medical fields, including oncology, inflammatory diseases, musculoskeletal conditions, cardiometabolic disorders, and rare diseases, IAG utilizes its DYNAMIKA™ platform to integrate AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time oversight of clinical trials.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.